{
    "organizations": [],
    "uuid": "fc8f2601bbcd8cc91f9d67764e441cc5f0002d01",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-us-fda-expands-approval-of-gilenya/brief-u-s-fda-expands-approval-of-gilenya-to-treat-multile-sclerosis-in-children-idUSFWN1SI1FL",
    "ord_in_thread": 0,
    "title": "BRIEF-U.S. FDA expands approval of Gilenya to treat multile sclerosis in children",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 11 (Reuters) - Novartis AG:\n* U.S. FDA SAYS APPROVED GILENYA (FINGOLIMOD) TO TREAT RELAPSING MULTIPLE SCLEROSIS IN CHILDREN & ADOLESCENTS AGE 10 YRS & OLDER\n* U.S. FDA SAYS GRANTED THE APPROVAL OF GILENYA TO NOVARTIS Source text: ( reut.rs/2rD6Tej ) Further company coverage:\n ",
    "published": "2018-05-12T04:36:00.000+03:00",
    "crawled": "2018-05-12T02:43:08.014+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "novartis",
        "ag",
        "fda",
        "say",
        "approved",
        "gilenya",
        "fingolimod",
        "treat",
        "relapsing",
        "multiple",
        "sclerosis",
        "child",
        "adolescent",
        "age",
        "yr",
        "older",
        "fda",
        "say",
        "granted",
        "approval",
        "gilenya",
        "novartis",
        "source",
        "text",
        "company",
        "coverage"
    ]
}